Treatment
Bevacizumab clinical trials
We’re tracking 421 recruiting studies that include Bevacizumab, each written for real people, not researchers, below.
Recruiting studies
- NCT05281471RecruitingPhase 3
Tested drug for platinum-resistant ovarian cancer with bevacizumab
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Mobile, AlabamaAges 18 years+ - NCT07549412RecruitingPhase 3
New chemotherapy drugs for advanced colorectal cancer
This trial tests whether a new chemotherapy combination (precemtabart tocentecan, with or without bevacizumab) works better than a standard treatment for colorectal cancer that has spread and stopped responding to previous drugs. The goal is to find treatments that help people live longer with fewer side effects.
Lone Tree, ColoradoAges 18 years+ - NCT06618664RecruitingPhase 3
New triple combo vs standard therapy for advanced liver cancer
This trial tests a new combination of three drugs (SHR-8068, adebrelimab, and bevacizumab) against two standard immunotherapy combinations (sintilimab or atezolizumab plus bevacizumab) for people with advanced liver cancer who haven't had systemic treatment before. The goal is to see if the new combo works better for shrinking or controlling the cancer.
Hefei, AnhuiAges 18 years+ - NCT06323382Recruiting
Liver cancer: local therapy plus immunotherapy combo
This trial tests a combination of local treatments (like TACE or HAIC) with bevacizumab and an immunotherapy drug (PD-1/L1 inhibitor) for advanced liver cancer. It may be an option if you haven't had systemic therapy before or if your previous treatment stopped working.
Beijing, Beijing MunicipalityAges 18–80 - NCT06737913RecruitingPhase 2
Study of adebrelimab and bevacizumab with liver chemo for advanced liver cancer
This trial tests a combination of an immunotherapy drug (adebrelimab) and a targeted therapy (bevacizumab) given through a vein or directly into the liver artery, along with standard chemotherapy directly into the liver artery, for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink or control the cancer.
Lanzhou, GansuAges 18 years+ - NCT06550453RecruitingPhase 4
Immunotherapy plus chemo before surgery for RAS-mutated colorectal cancer
This trial tests a combination of immunotherapy (pembrolizumab) plus targeted therapy (bevacizumab) and chemotherapy (CapeOX) given before surgery for a specific type of locally advanced colorectal cancer. It is designed for patients whose tumors have a RAS mutation, are BRAF normal, and are microsatellite stable.
Xi'an, ShaanxiAges 18 years+ - NCT07283367RecruitingPhase 1/Phase 2
New drug combo for advanced colorectal cancer
This trial tests a new combination of targeted therapies for people with advanced colorectal cancer that has a certain genetic pattern (non-MSI-H, no BRAF V600E mutation). It aims to see if the combination can shrink tumors or slow the cancer's growth.
GuangzhouAges 18 years+ - NCT05727163RecruitingPhase 2
Liver-directed chemotherapy versus standard chemotherapy for RAS-mutated CRC
This Phase 2 study tests whether delivering chemotherapy directly into the liver (with an IV medicine added, depending on the group) works better than standard chemotherapy given through a vein. It is for people whose colorectal cancer has spread to the liver but can’t be removed by surgery yet.
Guangzhou, GuangdongAges 18–75 - NCT07327788RecruitingPhase 2
Study of QL1706, bevacizumab, and chemo infusion for liver cancer with portal vein clot
This trial tests a combination of three treatments for people with advanced liver cancer that has spread into the main portal vein. The goal is to see if this therapy can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT07564141RecruitingPhase 3
New Drug for Recurrent Ovarian Cancer After Chemotherapy
This study tests a new medicine called Rina-S (with or without a blood vessel-blocking drug) compared to standard chemotherapy options for ovarian cancer that has come back after initial treatment. The goal is to see if Rina-S works better and is safer than current standard care.
Danbury, ConnecticutAges 18 years+ - NCT03303495RecruitingPhase 3
Second-line chemo with or without bevacizumab for colon cancer
This Phase 3 study compares two treatment plans for people with metastatic colorectal cancer that got worse or caused side effects after first chemotherapy. It looks at whether adding bevacizumab (a medicine that targets blood vessels feeding tumors) improves outcomes versus using a different chemotherapy approach.
Guangzhou, GuangdongAges 18 years+ - NCT04919629RecruitingPhase 2
Tested treatments for recurrent ovarian cancer with fluid buildup
This Phase 2 study tests whether adding two medicines—APL-2 plus pembrolizumab or pembrolizumab plus bevacizumab—works better than bevacizumab alone for recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also focuses on people who have symptoms from cancer-related fluid (ascites or pleural effusion).
Buffalo, New YorkAges 18 years+ - NCT05970666RecruitingPhase 2
TACE plus immunotherapy and VEGF drug for unresectable liver cancer
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
Xiamen, FujianAges 18–75 - NCT05992220RecruitingPhase 2
Immunotherapy with or without radiation for liver cancer
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
SeoulAges 20–79 - NCT06265350Recruiting
Freezing lung tumors plus immunotherapy for liver cancer with lung spread
This study tests a combination of treatments—freezing the lung tumors (cryoablation) plus two drugs (cardonilizumab and bevacizumab)—for people with liver cancer that has spread only to their lungs. It may be an option if your first treatment stopped working but your liver tumors are under control.
Guanzhou, GuangdongAges 18–75 - NCT06293014RecruitingPhase 2
TAS-102 with bevacizumab for colorectal cancer maintenance
This trial tests a combination of two drugs, TAS-102 and bevacizumab, as a follow-up maintenance treatment for people with advanced colorectal cancer. The goal is to see if this treatment can keep the cancer from growing after initial chemotherapy and bevacizumab therapy.
Zhengzhou, HenanAges 18 years+ - NCT06510582RecruitingPhase 1/Phase 2
Bevacizumab injection for chronic subdural hematoma
This trial tests if injecting bevacizumab into the artery that supplies the covering of the brain can help treat chronic subdural hematoma (a slow-growing collection of blood on the brain's surface). It may offer an alternative to surgery for some patients.
Camden, New JerseyAges 18 years+ - NCT06558227RecruitingPhase 2
ZG005 with bevacizumab vs sintilimab with bevacizumab for advanced liver cancer
This trial tests a new drug combination (ZG005 plus bevacizumab) against a standard combination (sintilimab plus bevacizumab) in people with advanced liver cancer that has spread or cannot be surgically removed. The goal is to see which combination works better and is safe.
Chengdu, SichuanAges 18–75 - NCT06595355RecruitingPhase 2/Phase 3
Study of eye injections with or without curcumin for diabetic eye swelling
This trial tests whether adding oral curcumin (a natural supplement) to standard eye injections (bevacizumab) improves treatment for diabetic macular edema, a swelling in the back of the eye that can affect vision.
Isfahan, Isfahan University of Medical SciencesAges 40 years+ - NCT06755684RecruitingPhase 2
Pre-surgery targeted drug combo for EGFR-mutant lung cancer
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07085169RecruitingPhase 2
Low-dose chemo combo for advanced colorectal cancer
This trial tests a lower dose of a chemotherapy pill (trifluridine/tipiracil) combined with bevacizumab for advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can help control the cancer with fewer side effects.
SanmingAges 60 years+ - NCT07192185RecruitingPhase 2
Chemo plus immunotherapy for advanced liver cancer after first treatment fails
This trial tests a new combination of chemotherapy (FOLFOX) plus atezolizumab and bevacizumab for people with advanced liver cancer that has grown after having atezolizumab and bevacizumab alone. The goal is to see if adding chemo helps stop the cancer from growing further.
Guangzhou, GuangdongAges 18–75 - NCT06819007RecruitingPhase 3
Study of trastuzumab deruxtecan plus bevacizumab for HER2-positive ovarian cancer
This trial tests whether adding trastuzumab deruxtecan to standard maintenance therapy with bevacizumab works better than bevacizumab alone for people with advanced ovarian cancer that has the HER2 protein. It is for those who have finished initial chemotherapy plus bevacizumab and are now starting maintenance treatment.
Burbank, CaliforniaAges 18 years+ - NCT07263438RecruitingPhase 2
Trimipramine, atezolizumab, and bevacizumab for recurrent glioblastoma
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
Basel, BaselAges 18 years+
What Bevacizumab is being studied for
Conditions with recruiting Bevacizumab studies.
Common questions
- Are there clinical trials studying Bevacizumab?
- Yes. Clin2 currently lists 421 recruiting studies that include Bevacizumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Bevacizumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Bevacizumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Bevacizumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.